Market News & Trends
Tjoapack Continues to Expand its Global Infrastructure With Strategic Investments in Injectable Packaging & Cold Chain Capabilities
Tjoapack, the global or a leading contract packaging organization (CPO) serving the pharmaceutical industry, has announced a significant expansion of its contract packaging and cold…
PCI Pharma Services to Provide Updates on New Manufacturing Facility
PCI Pharma Services will use the BIO International Convention, June 16-19 in Boston, as a platform to introduce its new purpose-built facility for large-scale sterile fill-finish…
AstriVax Therapeutics Initiates Clinical Development of a Hepatitis B Immunotherapy Using Launch-iT Technology
AstriVax Therapeutics NV recently announced the start of clinical development with AVX70371 for chronic hepatitis B virus (HBV) infection. The phase I RUBY study (NCT06989788)…
Conduit Pharmaceuticals Enters Joint Development Agreement With Manoira
Conduit Pharmaceuticals Inc. recently announced it has entered into a joint development agreement with Manoira Corporation. Under the terms of the joint development agreement, Manoira…
HCW Biologics Completes Deliverable & Solidifies License Agreement With WY Biotech
HCW Biologics Inc. and WY Biotech Co., Ltd. recently announced WY Biotech has completed its due diligence related to HCWB’s technology transfer report, including the…
Elicio Therapeutics Secures $10 Million in Financing
Elicio Therapeutics, Inc. recently announced it has entered a $10-million senior secured promissory note with existing investor, GKCC, LLC. The proceeds from the Note Financing,…
Trethera Secures New License, Strengthening TRE-515 Intellectual Property Portfolio & Extending Market Exclusivity to 2045
Trethera Corporation recently announced it entered an exclusive, worldwide licensing agreement with the University of California, Los Angeles (UCLA). The license expands Trethera’s intellectual property…
Rilzabrutinib Granted Orphan Drug Designation in the US for Sickle Cell Disease
The US FDA has granted orphan drug designation to rilzabrutinib, a novel, advanced, oral, reversible Bruton's tyrosine kinase (BTK) inhibitor that works via multi-immune modulation,…
Medicines Discovery Catapult & the Francis Crick Institute Partner to Support KQ Labs, a Leading Accelerator for Life Sciences Innovators
Medicines Discovery Catapult (MDC) and the Francis Crick Institute are pleased to announce a new strategic partnership to support the delivery of KQ Labs, a…
Symeres & Yoneda Labs Use AI to Optimize Cross-Coupling Reactions
Yoneda Labs, a leader in computational tools for reaction optimization, has successfully collaborated with Symeres, a leading transatlantic, small molecule contract research and manufacturing organization.…
Coya Therapeutics Announces Issuance of New Patent Protecting Methods of Producing Recombinant Human Interleukin-2 Liquid Formulations
Coya Therapeutics, Inc. recently announced the issuance of a US patent relevant to its investigational ready-to-use (RTU) liquid formulation of IL-2. In particular, the US…
Fujifilm Rebrands Life Sciences Companies to Strengthen Position as Strategic Partners for Life, Offering End-to-End Solutions
FUJIFILM Corporation's Life Sciences Group companies, a portfolio of businesses offering products, services and comprehensive solutions that span all stages of therapeutic development from discovery…
Kymera Therapeutics Announces Positive First-in-Human Results From Phase 1 Trial of a First-in-Class, Oral STAT6 Degrader
Kymera Therapeutics, Inc. recently announced positive clinical results from the Phase 1 healthy volunteer study of KT-621, its first-in-class, oral STAT6 degrader medicine. “Our primary objective…
CAR-T Therapies Need to Overcome Current Limitations to Unlock Promising Treatment Possibilities for Solid Tumors
CAR-Ts are revolutionizing the treatment of blood cancers, such as B-cell acute lymphocytic leukemia. However, their success has not yet extended to the realm of…
Curevo Enrolls First Participants in Phase 2 Extension Trial
Curevo Vaccine recently announced the enrollment of the first patients in a Phase 2 extension trial of its investigational shingles vaccine, amezosvatein. “I’m so proud…
BioNTech & Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop & Co-Commercialize Next-Generation Bispecific Antibody Candidate Broadly for Multiple Solid Tumor Types
BioNTech SE and Bristol Myers Squibb recently announced they have entered into an agreement for the global co-development and co-commercialization of BioNTech’s investigational bispecific antibody…
CERo Therapeutics Doses First Patient With CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations
CERo Therapeutics Holdings, Inc. recently announced it has dosed the first patient in its Phase 1 clinical trial of CER-1236. The patient was dosed at…
Cellares & Mitsui Fudosan Announce the First IDMO Smart Factory for Commercial-Scale Cell Therapy Manufacturing in Japan
Cellares, in collaboration with Mitsui Fudosan, recently announced the establishment of Japan’s first next-gen commercial production site for CAR-T cell therapies. The facility is under…
Sibeprenlimab's Priority Review Highlights Potential to Differentiate in IgAN Space
Otsuka Pharmaceutical recently announced that the FDA has accepted for review the Biologics License Application (BLA) for sibeprenlimab, which acts as A Proliferation Inducing Ligand…
Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 Trial of Descartes-08 in Patients With Myasthenia Gravis
Cartesian Therapeutics, Inc. recently announced the first participant has been enrolled in its Phase 3 AURORA trial of Descartes-08 in patients with myasthenia gravis (MG).…
